Cenobamate (CNB) is a new antiseizure medication (ASM) that has been approved by the US Food and Drug Administration in November 2019, and in March 2021 by the European Medicines Agency for the adjunctive treatment of focal onset seizures in adults. CNB is a novel tetrazole-derived carbamate compound with one chiral center. Dual, complementary mechanisms of action may contribute to its antiseizure activity. CNB has been shown to reduce neuronal excitability by enhancing the fast and slow inactivation of sodium channels and preferentially inhibiting the persistent component of the sodium channel current.
9
OCT
OCT
0